Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erdal Cavusoglu

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Progress in Cardiovascular Diseases|June 30, 2004
Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitorsSpyros Kokolis, Erdal Cavusoglu, Luther T Clark, et al.
The Journal of Invasive Cardiology|March 8, 2007
Impact of gender on in-hospital percutaneous coronary interventional outcomes in African-AmericansShyam Poludasu, Erdal Cavusoglu, Luther T Clark, et al.
The Journal of Invasive Cardiology|September 3, 2008
A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratoryJonathan D Marmur, Manish Lakhani, Soumaya El Rouby, et al.
American Heart Journal|October 31, 2006
Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trialJonathan D Marmur, Cristina A Mitre, Elliot Barnathan, et al.
Journal of Cardiovascular Pharmacology|February 24, 2005
Direct thrombin inhibitor use during percutaneous coronary interventionSpyros Kokolis, Luther T Clark, Erdal Cavusoglu, et al.
The Journal of Invasive Cardiology|February 7, 2008
High-dose tirofiban administered as bolus-only during percutaneous coronary interventionJonathan D Marmur, Shyam Poludasu, Ajay Agarwal, et al.
The American Journal of Cardiology|April 14, 2009
Effect of hemoglobin level on long-term all-cause mortality after percutaneous coronary intervention in African-AmericansShyam Poludasu, Jonathan D Marmur, Jeremy Weedon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|July 27, 2004
Current status of rotational atherectomyErdal Cavusoglu, Annapoorna S Kini, Jonathan D Marmur, et al.
The Journal of Invasive Cardiology|December 8, 2009
Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary interventionJonathan D Marmur, Renee P Bullock-Palmer, Shyam Poludasu, et al.
Thrombosis and Haemostasis|September 1, 2009
Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary interventionShyam Poludasu, Jonathan D Marmur, Jeremy Weedon, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Progress in Cardiovascular Diseases|June 30, 2004
Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitorsSpyros Kokolis, Erdal Cavusoglu, Luther T Clark, et al.
The Journal of Invasive Cardiology|March 8, 2007
Impact of gender on in-hospital percutaneous coronary interventional outcomes in African-AmericansShyam Poludasu, Erdal Cavusoglu, Luther T Clark, et al.
The Journal of Invasive Cardiology|September 3, 2008
A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratoryJonathan D Marmur, Manish Lakhani, Soumaya El Rouby, et al.
American Heart Journal|October 31, 2006
Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trialJonathan D Marmur, Cristina A Mitre, Elliot Barnathan, et al.
Journal of Cardiovascular Pharmacology|February 24, 2005
Direct thrombin inhibitor use during percutaneous coronary interventionSpyros Kokolis, Luther T Clark, Erdal Cavusoglu, et al.
The Journal of Invasive Cardiology|February 7, 2008
High-dose tirofiban administered as bolus-only during percutaneous coronary interventionJonathan D Marmur, Shyam Poludasu, Ajay Agarwal, et al.
The American Journal of Cardiology|April 14, 2009
Effect of hemoglobin level on long-term all-cause mortality after percutaneous coronary intervention in African-AmericansShyam Poludasu, Jonathan D Marmur, Jeremy Weedon, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|July 27, 2004
Current status of rotational atherectomyErdal Cavusoglu, Annapoorna S Kini, Jonathan D Marmur, et al.
The Journal of Invasive Cardiology|December 8, 2009
Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary interventionJonathan D Marmur, Renee P Bullock-Palmer, Shyam Poludasu, et al.
Thrombosis and Haemostasis|September 1, 2009
Red cell distribution width (RDW) as a predictor of long-term mortality in patients undergoing percutaneous coronary interventionShyam Poludasu, Jonathan D Marmur, Jeremy Weedon, et al.
Pageof 6